Omeros (OMER) Shares Outstanding (Diluted Average) (2019 - 2026)
Omeros' (OMER) quarterly Shares Outstanding (Diluted Average) came in at $90.1 million in Q1 2026, up 55.22% year-on-year from $58.1 million in Q1 2025, and up 55.22% quarter-over-quarter from $58.1 million in Q1 2025.
Omeros (OMER) Shares Outstanding (Diluted Average) (2019 - 2026) Analysis & Trends
Omeros has disclosed Shares Outstanding (Diluted Average) across 7 years of filings, most recently posting $90.1 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $90.1 million, up 55.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.1 million (up 55.22% YoY), and the FY2022 annual result was $62.7 million, up 0.63% from the prior year.
- Shares Outstanding (Diluted Average) came in at $90.1 million for Q1 2026 at Omeros, up from $58.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $90.1 million in Q1 2026 to a low of $58.1 million in Q1 2025.
- The 4-year median for Shares Outstanding (Diluted Average) is $62.7 million (2022), against an average of $65.6 million.
- Across the five-year window, Shares Outstanding (Diluted Average) climbed 0.17% in 2023 and jumped 55.22% in 2026, its largest moves.
- Omeros' Shares Outstanding (Diluted Average) stood at $62.7 million in 2022, then advanced by 0.16% to $62.8 million in 2023, then slipped by 7.61% to $58.1 million in 2025, then surged by 55.22% to $90.1 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $90.1 million (Q1 2026), $58.1 million (Q1 2025), and $62.8 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 92.44 Mn |
| 10 | Omeros | 628.56 Mn | 493.24 Mn | 9.31 Mn | 90.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.12 Mn |
| Mar 31, 2025 | 58.06 Mn |
| Jun 30, 2023 | 62.84 Mn |
| Mar 31, 2023 | 62.83 Mn |
| Dec 31, 2022 | 62.74 Mn |
| Sep 30, 2022 | 62.73 Mn |
| Jun 30, 2022 | 62.73 Mn |
| Mar 31, 2022 | 62.72 Mn |
| Dec 31, 2021 | 62.34 Mn |
| Sep 30, 2021 | 62.51 Mn |
| Jun 30, 2021 | 62.37 Mn |
| Mar 31, 2021 | 61.93 Mn |
| Dec 31, 2020 | 57.18 Mn |
| Sep 30, 2020 | 55.68 Mn |
| Jun 30, 2020 | 54.41 Mn |
| Dec 31, 2019 | 49.52 Mn |